Ketamine and brain opioid receptors for suicidal thoughts
Treatments studied
Part of Mental health clinical trials.
This study tests how ketamine affects brain chemicals linked to suicidal thoughts in people with depression. You will receive ketamine and have brain scans (PET and MRI) to see if it changes activity in opioid receptors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a current major depressive episode (unipolar, not bipolar).
- You cannot have ever abused or been dependent on ketamine.
- No suicide attempt in the past month, and no active plan/intent to harm yourself.
- No lifetime history of schizophrenia, schizoaffective disorder, or bipolar disorder.
- You must not be taking antidepressants within 14 days (or 6 weeks for fluoxetine) or benzodiazepines within 1 day before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.
This study tests if ketamine can help reduce suicidal thoughts in people with major depression. You'll receive ketamine treatment and be monitored closely.
This study tests whether ketamine (a medication) combined with a specific type of therapy called DBT can help people with treatment-resistant depression and borderline personality disorder who are having thoughts of suicide. You would receive ketamine infusions alongside structured therapy sessions over 6 months.
This trial studies how ketamine affects brain circuits in people with depression compared to healthy volunteers. It involves a single infusion of ketamine and brain scans before and after.
This study compares ketamine alone to ketamine combined with psychotherapy for treating depression. It may help if you have moderate to severe depression and want to see if adding talk therapy improves results.
This trial is for people with severe major depression who may benefit from a single dose of ketamine. Researchers want to see if certain biomarkers in your blood or brain can predict how well ketamine works for you.
Hear when a new Major Depressive Disorder (MDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.